A PHASE 2, INTERNATIONAL, MULTICENTER, SINGLE-ARM, OPEN-LABEL STUDY TO EVALUATE THE EFFICACY AND SAFETY OF CC-486 (ORAL AZACITIDINE) IN SUBJECTS WITH MYELODYSPLASTIC SYNDROMES WHO FAIL TO ACHIEVE AN OBJECTIVE RESPONSE TO TREATMENT WITH AZACITIDINE FOR INJECTIONOR DECITABINE

Type of Cancer
Leukemia

Site
Hackensack

Sponsor
Celgene

Protocol Number
CC-486-MDS-006

To Learn More Call
201-510-0910